Anti‑cancer effects of the circadian clock modulating compound SR9009 in chordoma cell lines
- 11 September 2026
- journal article
- research article
- Published by Taylor & Francis in Chronobiology International
- p. 1-10
Abstract
Chordoma is a rare, low-grade axial skeleton carcinoma originating from notochord remnants. These tumors are usually seen in the skull base, spine, and sacrum and have an annual incidence of 0.08% ...Keywords
Funding Information
- Health Institutes of Türkiye (2023-A1-01)
This publication has 44 references indexed in Scilit:
- Phosphorylation of CLOCK and BMAL1 —a key regulatory mechanism in the mammalian circadian clockworkFEBS Letters, 2025
- Erwin Bünning and Wolfgang Engelmann: establishing the involvement of the circadian clock in photoperiodismJournal of Comparative Physiology A, 2024
- Activation of Wnt Pathway Suppresses Growth of MUG-Chor1 Chordoma Cell LineCell Biochemistry and Biophysics, 2023
- REV-ERBα agonist SR9009 suppresses IL-1β production in macrophages through BMAL1-dependent inhibition of inflammasomeBiochemical Pharmacology, 2021
- Rationale for the advancement of PI3K pathway inhibitors for personalized chordoma therapyJournal of Neuro-Oncology, 2020
- The role of TNF-α in chordoma progression and inflammatory pathwaysCellular Oncology, 2019
- Characterization of the endolysosomal system in human chordoma cell lines: is there a role of lysosomes in chemoresistance of this rare bone tumor?Histochemistry and Cell Biology, 2018
- In Vitro Tumorigenic Assay: Colony Forming Assay for Cancer Stem Cells2017
- Emerging role of nanog in tumorigenesis and cancer stem cellsInternational Journal of Cancer, 2013
- Establishment and characterization of a novel chordoma cell line: CH22Journal of Orthopaedic Research, 2012